Table 5.
Currently recruiting and ongoing clinical trials of tyrosine kinase and immune checkpoint inhibitors in ATC.
| Currently Recruiting | ||||
|---|---|---|---|---|
| Study title | Phase | Drug(s) | Year of start | Estimated year of completion |
| Trametinib in combination with paclitaxel in the treatment of ATC NCT03085056 | I | Trametinib Paclitaxel | 2017 | 2020 |
| A phase II study of MLN0128 in metastatic ATC NCT02244463 | II | MLN0128 | 2014 | 2022 |
| Nexavar for neoadjuvant treatment of ATC NCT03565536 | II | Sorafenib | 2018 | 2019 |
| Pembrolizumab in anaplastic/undifferentiated thyroid cancer NCT02688608 | II | Pembrolizumab | 2016 | 2020 |
| Ceritinib in mutation and oncogene directed therapy in thyroid cancer NCT02289144 | II | Ceritinib | 2014 | 2021 |
| Nivolumab plus ipilimumab in thyroid cancer NCT03246958 | II | Nivolumab Ipilimumab | 2017 | 2025 |
| Atezolizumab with chemotherapy in treating patients with anaplastic or poorly differentiated thyroid cancer NCT03181100 | II | Atezolizumab Bevacizumab Cobimetinib Nab-paclitaxel Paclitaxel Vemurafenib |
2017 | 2023 |
| Ongoing | ||||
| Phase II study assessing the efficacy and safety of lenvatinib for ATC NCT02726503 | II | Lenvatinib | 2016 | 2020 |
| Immunotherapy and stereotactic body radiotherapy (SBRT) for metastatic ATC NCT03122496 | I | Durvalumab Tremelimumab SBRT |
2017 | 2020 |
| Pembrolizumab, chemotherapy and radiation therapy with or without surgery in treating patients with ATC NCT03211117 | II | Docetaxel Doxorrubicin hydrochloride IMRT Pembrolizumab |
2017 | 2019 |
| Phase I/II study of PDR001 in patients with advanced malignancies NCT02404441 | I II |
PDR001 | 2015 | 2020 |
| Intensity-modulated radiation therapy and paclitaxel with or without pazopanib hydrochloride in treating patients with anaplastic thyroid cancer NCT01236547 | II | IMRT Paclitaxel Pazopanib hydrochloride |
2010 | 2019 |
| Pazopanib hydrochloride in treating patients with advanced thyroid cancer NCT00625846 | II | Pazopanib hydrochloride | 2008 | |
| Treatment with recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with anaplastic thyroid cancer: a proof of concept study EudraCT: 2017-003028-59 | IV | Interleukin 1 receptor antagonist | 2018 | |
| A phase II study to investigate the efficacy of RAD001 (Afinitor ®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma EudraCT: 2009-016669-27 | II | Everolimus | 2010 | |
| An open-label phase 2 multi-cohort trial of nivolumab in advanced or metastatic malignancies EudraCT: 2016-000461-23 | II | nivolumab | 2017 | |